『十类』特殊人群:感冒用药黑名单 !

2016-04-13 药评中心 药评中心

普通感冒也叫上呼吸道病毒感染,是最常见的感染性疾病。感冒缺乏特异性治疗,并多能自行缓解,抗病毒治疗没有明显效果。现有的抗感冒药只能暂时缓解感冒症状,无法治愈疾病。但若使用不当却能给对孕妇、儿童等特殊人群带来严重后果。下面让我们一起盘点十类特殊人群感冒用药黑名单。 1、妊娠期妇女 1.慎用对乙酰氨基酚:妊娠晚期用药可能导致动脉导管产前收缩,妊娠期经常使用可能与幼童时期哮喘有关。

普通感冒也叫上呼吸道病毒感染,是最常见的感染性疾病。感冒缺乏特异性治疗,并多能自行缓解,抗病毒治疗没有明显效果。现有的抗感冒药只能暂时缓解感冒症状,无法治愈疾病。但若使用不当却能给对孕妇、儿童等特殊人群带来严重后果。下面让我们一起盘点十类特殊人群感冒用药黑名单。

1、妊娠期妇女

1.慎用对乙酰氨基酚:妊娠晚期用药可能导致动脉导管产前收缩,妊娠期经常使用可能与幼童时期哮喘有关。
 
2.慎用伪麻黄碱:可通过胎盘。
 
3.慎用氯苯那敏:可通过胎盘。尚无本药的生殖毒性研究资料。
 
4.妊娠3个月内禁用愈创甘油醚:动物研究证明本药可致畸和死胎。
 
5.禁用阿司匹林、布洛芬:妊娠前3个月服用可能与畸形(颚裂、心脏畸形)危险性升高有关;妊娠后3个月服用可能导致孕期延长,母体子宫的收缩受抑和胎儿的心肺毒性,及母亲和胎儿的出血风险增加。
 
6.禁用可待因:可使胎儿成瘾,引起新生儿戒断症状;分娩期服用可引起新生儿呼吸抑制。
 
7. 禁用苯海拉明、金刚烷胺:前者可使婴儿腭裂、腹股沟疝和泌尿生殖器官畸形发生率增高;后者也有致畸胎的作用。
 
2、哺乳期妇女

1.慎用对乙酰氨基酚:在乳汁中可达一定浓度,虽然在哺乳婴儿尿中未发现本药及其代谢产物排除,但哺乳期妇女慎用。
 
2.禁用阿司匹林、布洛芬:可随乳汁排泄,长期大剂量用药可能对乳儿产生不良反应。
 
3.慎用可待因:可随乳汁排泄。如使用本药时建议使用最低剂量、持续最短的时间,并观察乳儿是否有睡眠增加、进食困难、呼吸困难或疲倦的症状。
 
4.慎用伪麻黄碱、咖啡因:可随乳汁分泌。
 
5.慎用氯苯那敏:有抗M胆碱受体作用,可能抑制乳汁分泌。
 
6.禁用苯海拉明、金刚烷胺:可从乳汁小量排出,使婴儿产生不良反应。
 
3、儿   童

1.禁用(<1岁)或慎用(<3岁)阿司匹林:引起瑞氏综合征。
 
2.新生儿、婴儿禁用金刚烷胺。
 
3.不要给6岁以下儿童使用非处方类感冒咳嗽药:包括抗组胺药氯苯那敏、苯海拉明;鼻减充血药伪麻黄碱、麻黄碱、去氧肾上腺素、羟甲唑啉、塞洛唑啉;镇咳药右美沙芬、福尔可定;祛痰药愈创甘油醚、吐根。(美国、英国、加拿大、澳大利亚等)。

4、特殊职业者

特殊职业者,包括机动车驾驶员、高空作业者及操纵机器或精密仪器者等。
 
1.避免使用氯苯那敏、苯海拉明:能阻断中枢H1受体引起的中枢抑制,导致镇静、嗜睡等副作用。
 
2.避免使用金刚烷胺:能引起头痛、眩晕、焦虑、幻觉、精神错乱、共济失调。每日最后一次服药时间应在下午4时前,以避免失眠。
 
3.避免使用右美沙芬:能引起头晕、头痛、嗜睡、易激动等不良反应。过量可引起神志不清,支气管痉挛,呼吸抑制。
 
5、肝功能不全者

1.慎用解热镇痛成分:对乙酰氨基酚、布洛芬、阿司匹林。解热镇痛药的肝毒性与剂量有关。
 
2.慎用右美沙芬。
 
6、肾功能不全者

1.慎用解热镇痛成分:对乙酰氨基酚、布洛芬、阿司匹林。解热镇痛药对肾脏有毒性,长期大量服用,可出现肾绞痛,甚至导致肾功能衰竭。
 
2.慎用苯海拉明、金刚烷胺:其代谢明显减慢,易蓄积产生不良反应。
 
3.肾炎病人禁用愈创甘油醚:大量服用愈创甘油醚可导致尿结石形成。
 
7、消化系统疾病患者

1.慎用咖啡因:对胃黏膜有刺激作用。
 
2.慎用愈创甘油醚:属恶心性祛痰药,口服后对胃粘膜有刺激性。
 
3.活动性消化溃疡患者禁用:布洛芬、阿司匹林。增加胃肠溃疡、胃肠出血、胃肠穿孔风险,其风险可能是致命的。
 
8、呼吸系统疾病患者

1.哮喘、鼻炎、鼻息肉综合征患者:禁用阿司匹林。可诱发以鼻窦炎、哮喘和阿司匹林过敏“三联症”为特征的阿司匹林哮喘综合征。
 
2.有解热镇痛药后诱发哮喘、鼻炎、荨麻疹史者:禁用阿司匹林、布洛芬。有交叉过敏反应。
 
3.支气管哮喘患者:慎用布洛芬。可致轻度的支气管痉挛或加重哮喘发作。
 
4.阿司匹林过敏者:慎用对乙酰氨基酚。
 
9、心血管系统疾病患者

1.高血压、心功能不全、心绞痛患者慎用伪麻黄碱及含麻黄的中成药。
 
2.高血压、心功能不全、心绞痛患者慎用布洛芬。可引起水钠潴留及水肿。
 
3.冠脉搭桥术围手术期患者:禁用布洛芬。布洛芬可增加严重心血管血栓、心肌梗死和脑卒中的风险,其风险可能是致命的。
 
10、血液系统疾病患者

1.血友病、血小板减少症:慎用对乙酰氨基酚、布洛芬。对血小板的抑制作用,可能加重出血倾向。
 
2.血友病、血小板减少症:禁用阿司匹林。通过减少PG合成,从而抑制血小板聚集,加重凝血障碍。
 
3.粒细胞减少症:慎用对乙酰氨基酚、布洛芬。可引起粒细胞减少。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1635524, encodeId=30b616355247d, content=<a href='/topic/show?id=c72e6e9866b' target=_blank style='color:#2F92EE;'>#特殊人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67986, encryptionId=c72e6e9866b, topicName=特殊人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a3922492851, createdName=124987e8m14暂无昵称, createdTime=Fri Jun 17 20:15:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755118, encodeId=fc341e55118a0, content=<a href='/topic/show?id=2f82103280eb' target=_blank style='color:#2F92EE;'>#黑名单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103280, encryptionId=2f82103280eb, topicName=黑名单)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f52536838019, createdName=zhty5349, createdTime=Tue Oct 25 06:15:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85105, encodeId=6f94851054e, content=值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Mon May 09 18:37:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85106, encodeId=c9ae85106df, content=值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Mon May 09 18:37:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78402, encodeId=ff26e8402c1, content=学习了长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Thu Apr 14 22:08:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78388, encodeId=257ae83882f, content=真的非常小心呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160327/IMG56F7D60F101C42150.jpg, createdBy=3ab61705271, createdName=1de8e1afm39(暂无匿称), createdTime=Thu Apr 14 21:41:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77893, encodeId=9f46e789377, content=谨慎用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 17:51:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77734, encodeId=a830e7734a0, content=用药需谨慎, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52741685696, createdName=老刘2991, createdTime=Wed Apr 13 22:02:00 CST 2016, time=2016-04-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1635524, encodeId=30b616355247d, content=<a href='/topic/show?id=c72e6e9866b' target=_blank style='color:#2F92EE;'>#特殊人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67986, encryptionId=c72e6e9866b, topicName=特殊人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a3922492851, createdName=124987e8m14暂无昵称, createdTime=Fri Jun 17 20:15:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755118, encodeId=fc341e55118a0, content=<a href='/topic/show?id=2f82103280eb' target=_blank style='color:#2F92EE;'>#黑名单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103280, encryptionId=2f82103280eb, topicName=黑名单)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f52536838019, createdName=zhty5349, createdTime=Tue Oct 25 06:15:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85105, encodeId=6f94851054e, content=值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Mon May 09 18:37:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85106, encodeId=c9ae85106df, content=值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Mon May 09 18:37:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78402, encodeId=ff26e8402c1, content=学习了长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Thu Apr 14 22:08:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78388, encodeId=257ae83882f, content=真的非常小心呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160327/IMG56F7D60F101C42150.jpg, createdBy=3ab61705271, createdName=1de8e1afm39(暂无匿称), createdTime=Thu Apr 14 21:41:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77893, encodeId=9f46e789377, content=谨慎用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 17:51:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77734, encodeId=a830e7734a0, content=用药需谨慎, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52741685696, createdName=老刘2991, createdTime=Wed Apr 13 22:02:00 CST 2016, time=2016-04-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1635524, encodeId=30b616355247d, content=<a href='/topic/show?id=c72e6e9866b' target=_blank style='color:#2F92EE;'>#特殊人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67986, encryptionId=c72e6e9866b, topicName=特殊人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a3922492851, createdName=124987e8m14暂无昵称, createdTime=Fri Jun 17 20:15:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755118, encodeId=fc341e55118a0, content=<a href='/topic/show?id=2f82103280eb' target=_blank style='color:#2F92EE;'>#黑名单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103280, encryptionId=2f82103280eb, topicName=黑名单)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f52536838019, createdName=zhty5349, createdTime=Tue Oct 25 06:15:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85105, encodeId=6f94851054e, content=值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Mon May 09 18:37:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85106, encodeId=c9ae85106df, content=值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Mon May 09 18:37:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78402, encodeId=ff26e8402c1, content=学习了长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Thu Apr 14 22:08:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78388, encodeId=257ae83882f, content=真的非常小心呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160327/IMG56F7D60F101C42150.jpg, createdBy=3ab61705271, createdName=1de8e1afm39(暂无匿称), createdTime=Thu Apr 14 21:41:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77893, encodeId=9f46e789377, content=谨慎用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 17:51:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77734, encodeId=a830e7734a0, content=用药需谨慎, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52741685696, createdName=老刘2991, createdTime=Wed Apr 13 22:02:00 CST 2016, time=2016-04-13, status=1, ipAttribution=)]
    2016-05-09 jaysppr

    值得收藏

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1635524, encodeId=30b616355247d, content=<a href='/topic/show?id=c72e6e9866b' target=_blank style='color:#2F92EE;'>#特殊人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67986, encryptionId=c72e6e9866b, topicName=特殊人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a3922492851, createdName=124987e8m14暂无昵称, createdTime=Fri Jun 17 20:15:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755118, encodeId=fc341e55118a0, content=<a href='/topic/show?id=2f82103280eb' target=_blank style='color:#2F92EE;'>#黑名单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103280, encryptionId=2f82103280eb, topicName=黑名单)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f52536838019, createdName=zhty5349, createdTime=Tue Oct 25 06:15:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85105, encodeId=6f94851054e, content=值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Mon May 09 18:37:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85106, encodeId=c9ae85106df, content=值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Mon May 09 18:37:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78402, encodeId=ff26e8402c1, content=学习了长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Thu Apr 14 22:08:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78388, encodeId=257ae83882f, content=真的非常小心呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160327/IMG56F7D60F101C42150.jpg, createdBy=3ab61705271, createdName=1de8e1afm39(暂无匿称), createdTime=Thu Apr 14 21:41:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77893, encodeId=9f46e789377, content=谨慎用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 17:51:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77734, encodeId=a830e7734a0, content=用药需谨慎, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52741685696, createdName=老刘2991, createdTime=Wed Apr 13 22:02:00 CST 2016, time=2016-04-13, status=1, ipAttribution=)]
    2016-05-09 jaysppr

    值得分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1635524, encodeId=30b616355247d, content=<a href='/topic/show?id=c72e6e9866b' target=_blank style='color:#2F92EE;'>#特殊人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67986, encryptionId=c72e6e9866b, topicName=特殊人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a3922492851, createdName=124987e8m14暂无昵称, createdTime=Fri Jun 17 20:15:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755118, encodeId=fc341e55118a0, content=<a href='/topic/show?id=2f82103280eb' target=_blank style='color:#2F92EE;'>#黑名单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103280, encryptionId=2f82103280eb, topicName=黑名单)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f52536838019, createdName=zhty5349, createdTime=Tue Oct 25 06:15:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85105, encodeId=6f94851054e, content=值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Mon May 09 18:37:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85106, encodeId=c9ae85106df, content=值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Mon May 09 18:37:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78402, encodeId=ff26e8402c1, content=学习了长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Thu Apr 14 22:08:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78388, encodeId=257ae83882f, content=真的非常小心呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160327/IMG56F7D60F101C42150.jpg, createdBy=3ab61705271, createdName=1de8e1afm39(暂无匿称), createdTime=Thu Apr 14 21:41:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77893, encodeId=9f46e789377, content=谨慎用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 17:51:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77734, encodeId=a830e7734a0, content=用药需谨慎, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52741685696, createdName=老刘2991, createdTime=Wed Apr 13 22:02:00 CST 2016, time=2016-04-13, status=1, ipAttribution=)]
    2016-04-14 hekzn

    学习了长知识

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1635524, encodeId=30b616355247d, content=<a href='/topic/show?id=c72e6e9866b' target=_blank style='color:#2F92EE;'>#特殊人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67986, encryptionId=c72e6e9866b, topicName=特殊人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a3922492851, createdName=124987e8m14暂无昵称, createdTime=Fri Jun 17 20:15:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755118, encodeId=fc341e55118a0, content=<a href='/topic/show?id=2f82103280eb' target=_blank style='color:#2F92EE;'>#黑名单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103280, encryptionId=2f82103280eb, topicName=黑名单)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f52536838019, createdName=zhty5349, createdTime=Tue Oct 25 06:15:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85105, encodeId=6f94851054e, content=值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Mon May 09 18:37:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85106, encodeId=c9ae85106df, content=值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Mon May 09 18:37:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78402, encodeId=ff26e8402c1, content=学习了长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Thu Apr 14 22:08:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78388, encodeId=257ae83882f, content=真的非常小心呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160327/IMG56F7D60F101C42150.jpg, createdBy=3ab61705271, createdName=1de8e1afm39(暂无匿称), createdTime=Thu Apr 14 21:41:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77893, encodeId=9f46e789377, content=谨慎用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 17:51:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77734, encodeId=a830e7734a0, content=用药需谨慎, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52741685696, createdName=老刘2991, createdTime=Wed Apr 13 22:02:00 CST 2016, time=2016-04-13, status=1, ipAttribution=)]
    2016-04-14 1de8e1afm39(暂无匿称)

    真的非常小心呀

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1635524, encodeId=30b616355247d, content=<a href='/topic/show?id=c72e6e9866b' target=_blank style='color:#2F92EE;'>#特殊人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67986, encryptionId=c72e6e9866b, topicName=特殊人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a3922492851, createdName=124987e8m14暂无昵称, createdTime=Fri Jun 17 20:15:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755118, encodeId=fc341e55118a0, content=<a href='/topic/show?id=2f82103280eb' target=_blank style='color:#2F92EE;'>#黑名单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103280, encryptionId=2f82103280eb, topicName=黑名单)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f52536838019, createdName=zhty5349, createdTime=Tue Oct 25 06:15:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85105, encodeId=6f94851054e, content=值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Mon May 09 18:37:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85106, encodeId=c9ae85106df, content=值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Mon May 09 18:37:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78402, encodeId=ff26e8402c1, content=学习了长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Thu Apr 14 22:08:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78388, encodeId=257ae83882f, content=真的非常小心呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160327/IMG56F7D60F101C42150.jpg, createdBy=3ab61705271, createdName=1de8e1afm39(暂无匿称), createdTime=Thu Apr 14 21:41:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77893, encodeId=9f46e789377, content=谨慎用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 17:51:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77734, encodeId=a830e7734a0, content=用药需谨慎, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52741685696, createdName=老刘2991, createdTime=Wed Apr 13 22:02:00 CST 2016, time=2016-04-13, status=1, ipAttribution=)]
    2016-04-14 李继凯

    谨慎用药

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1635524, encodeId=30b616355247d, content=<a href='/topic/show?id=c72e6e9866b' target=_blank style='color:#2F92EE;'>#特殊人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67986, encryptionId=c72e6e9866b, topicName=特殊人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a3922492851, createdName=124987e8m14暂无昵称, createdTime=Fri Jun 17 20:15:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755118, encodeId=fc341e55118a0, content=<a href='/topic/show?id=2f82103280eb' target=_blank style='color:#2F92EE;'>#黑名单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103280, encryptionId=2f82103280eb, topicName=黑名单)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f52536838019, createdName=zhty5349, createdTime=Tue Oct 25 06:15:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85105, encodeId=6f94851054e, content=值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Mon May 09 18:37:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85106, encodeId=c9ae85106df, content=值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Mon May 09 18:37:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78402, encodeId=ff26e8402c1, content=学习了长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Thu Apr 14 22:08:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78388, encodeId=257ae83882f, content=真的非常小心呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160327/IMG56F7D60F101C42150.jpg, createdBy=3ab61705271, createdName=1de8e1afm39(暂无匿称), createdTime=Thu Apr 14 21:41:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77893, encodeId=9f46e789377, content=谨慎用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 17:51:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77734, encodeId=a830e7734a0, content=用药需谨慎, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52741685696, createdName=老刘2991, createdTime=Wed Apr 13 22:02:00 CST 2016, time=2016-04-13, status=1, ipAttribution=)]
    2016-04-13 老刘2991

    用药需谨慎

    0

相关资讯

国家对部分感冒药限售 6类药品须凭医院处方购买

  6类含麻黄碱药品必须凭医院处方购买   国家因何对部分感冒药限售?   部分感冒药的监管让有关部门挠头不已。   本月6日,国家食品药品监督管理局发布公告称,对氯雷伪麻缓释片、复方盐酸伪麻黄碱缓释胶囊、氨酚氯雷伪麻缓释片、那敏伪麻胶囊、扑尔伪麻片和复方布洛伪麻缓释片的说明书进行了核准,并于日前发布。按照修订后的说明书,这6类药品从非处方药变成处方药。   早在今年9月4日,国家食品药品

AHA 专家建议:高血压患者应用感冒药的7大注意事项

寒冷冬季,是感冒的高发季节。但你知道吗?有些治疗感冒的用于控制症状的非处方药也可能升高血压和损伤肾脏。造成这种损害的罪魁祸首可能是伪麻黄碱和其他治疗感冒的成分。 根据美国心脏学会(AHA)消息,流感可对高血压人群产生严重的健康风险,相比于其他慢性病人群,心血管疾病患者更有可能死于流感。因此控制这些人群的症状就显得尤为重要,但也有必要知道感冒治疗药物的潜在副作用。 高血压患者的注意